Aktienanalyse zu Edgewise Therapeutics Inc (EWTX)EWTXEdgewise Therapeutics Inc

Edgewise Therapeutics, Inc. is a biopharmaceutical company focused on cardiovascular diseases. The Company is advancing a cardiovascular pipeline targeting significant unmet needs, including hypertrophic cardiomyopathy, heart failure and other serious cardiovascular and cardio metabolic conditions. The Company's pipeline comprises the EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for HFpEF and EDG-003. EDG-7500 is a novel, oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with hypertrophic cardiomyopathy (HCM) and other diseases of diastolic dysfunction which is being studied in a multipart Phase 2 trial for the potential treatment of obstructive and nonobstructive HCM. The Company is also developing EDG-15400, which is in a Phase 1 trial of healthy adults with the future disease target of heart failure with preserved ejection fraction (HFpEF). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, Edgewise Therapeutics Inc (EWTX) is not a strong buy. The stock is trading at $37.19, which is below the analyst price targets of $57 from H.C. Wainwright and $60 from JPMorgan, indicating potential upside. However, the RSI is at 35.112, suggesting the stock is nearing oversold territory, but the recent 5-day change is -4.79%, indicating a downward trend. The main risk is the negative earnings per share (EPS) of -0.53 reported in the last quarter, which reflects ongoing financial challenges.